What Is Dose-Dense Chemotherapy? How Does It Improve Survival in Breast Cancer?

Tailored dose-dense adjuvant chemotherapy improved recurrence-free survival, event-free survival, and distant disease-free survival at 10 years.

What Is Dose-Dense Chemotherapy?

Dose-dense chemotherapy is a treatment approach administered at shorter intervals than standard chemotherapy, for example every two weeks. It aims to target the rate at which cancer cells grow and divide more effectively. It is used to improve overall survival and treatment responses in patients.

Adjuvant Treatment and the Rationale for Dose-Dense Therapy

Adjuvant treatment is additional therapy given after cancer surgery to reduce the risk of recurrence. Dose-dense chemotherapy aims to target cancer cell growth and division more effectively by administering chemotherapy at shorter intervals. This approach is used to improve treatment outcomes, particularly in high-risk cancers.

• Related topic: Dose-Dense CA for Breast Cancer Treatment – Cyclophosphamide and Doxorubicin

The PANTHER Trial

Tailored dose-dense adjuvant chemotherapy may improve long-term outcomes compared with standard adjuvant chemotherapy in patients with high-risk early breast cancer. These findings were published on July 17, 2024, in the Journal of Clinical Oncology and came from the final analysis of the phase 3 PANTHER trial.

The study showed that dose-dense treatment improved breast cancer recurrence-free survival, event-free survival, and distant disease-free survival at 10 years. However, there was no significant difference in overall survival between the treatment arms.

• Recurrence-free survival is the length of time after treatment during which cancer does not return;
• Event-free survival is the time a patient spends without a serious complication or disease progression;
• Distant disease-free survival is the length of time without cancer spreading to another part of the body.

The phase 3 PANTHER trial included women aged 18-65 who had undergone surgery for nonmetastatic, high-risk breast cancer.

Patients were randomly assigned to the following groups:

• The dose-dense treatment group (1001 patients) received a regimen of epirubicin and cyclophosphamide for 4 cycles every 2 weeks, followed by 4 cycles of docetaxel every 2 weeks, with doses adjusted according to a predefined algorithm based on hematologic and nonhematologic side effects.
• The control treatment group (1002 patients) received 3 cycles of fluorouracil, epirubicin, and cyclophosphamide every 3 weeks, followed by 3 cycles of docetaxel every 3 weeks. Patients could also receive radiotherapy, endocrine therapy, and trastuzumab according to national and local guidelines.

Results

At a median follow-up of 10.3 years:

• Patients receiving dose-dense treatment had a significantly longer interval without cancer recurrence than those in the control group (HR, 0.80; 95% CI, 0.65-0.98; P =0.030). Within 10 years, the recurrence rate was 18.6% in the dose-dense group and 22.3% in the control group.
• The experimental treatment also improved event-free survival (HR, 0.78; 95% CI, 0.65-0.94; P =0.009). This indicates that patients in the experimental group survived longer without a serious complication or disease progression. The 10-year event rate was 23.2% in the experimental group and 27.6% in the control group.
• The experimental treatment also improved distant disease-free survival (HR, 0.79; 95% CI, 0.64-0.98; P =0.030). This indicates that patients in the experimental group survived longer without cancer spreading to another part of the body. The 10-year event rate was 17.2% in the experimental group and 20.9% in the control group.
• There was no significant difference in overall survival between the groups (HR, 0.82; 95% CI, 0.65-1.04; P =0.109). This indicates that overall survival rates were similar in both groups. The 10-year event rate was 15.1% in the experimental group and 16.6% in the control group.

The researchers noted that there had been no new safety signals since the primary analysis and no new cases of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) had been reported. There were 3 AML/MDS cases in the experimental group and 2 in the control group.

The First Study

This is the first study to demonstrate improved outcomes with dose-dense chemotherapy compared with a control regimen of sequential standard-dose EC [epirubicin and cyclophosphamide] and docetaxel given every 3 weeks. These results demonstrate the superiority of dose-dense treatment schedules regardless of the comparator treatment.

Commentary

The results of this study clearly demonstrate that dose-dense chemotherapy is more effective than standard chemotherapy in patients with high-risk early breast cancer. Dose-dense treatment enables patients to survive longer without cancer recurrence, serious complications, or cancer spread. These findings suggest that dose-dense chemotherapy should be favored more often in treatment protocols and represent an important step toward improving patients' long-term survival rates.